ARTICLE | Clinical News
LX1032: Phase II started
July 13, 2009 7:00 AM UTC
Lexicon began a double-blind, placebo-controlled, dose-escalation, U.S. Phase II trial to evaluate up to 4 dose levels of oral LX1032 in about 28 patients for 4 weeks. LX1032 has Fast Track designatio...